January 2025's Promising Penny Stocks To Consider

As we step into 2025, global markets are showing a mixed performance with the S&P 500 and Nasdaq Composite closing out a strong year despite recent economic challenges such as declining PMI readings and revised GDP forecasts. Amid these market dynamics, investors often look for opportunities in less conventional areas like penny stocks, which refer to shares of smaller or newer companies that trade at lower prices. Although the term "penny stocks" may seem outdated, these investments can still offer significant value when backed by solid financial health and potential for growth.

Top 10 Penny Stocks

Name	Share Price	Market Cap	Financial Health Rating
DXN Holdings Bhd (KLSE:DXN)	MYR0.53	MYR2.54B	★★★★★★
Embark Early Education (ASX:EVO)	A$0.775	A$142.2M	★★★★☆☆
Hil Industries Berhad (KLSE:HIL)	MYR0.90	MYR298.75M	★★★★★★
ME Group International (LSE:MEGP)	£2.115	£796.96M	★★★★★★
Bosideng International Holdings (SEHK:3998)	HK$3.64	HK$41.63B	★★★★★★
Datasonic Group Berhad (KLSE:DSONIC)	MYR0.425	MYR1.18B	★★★★★★
Lever Style (SEHK:1346)	HK$0.86	HK$545.92M	★★★★★★
Begbies Traynor Group (AIM:BEG)	£0.964	£152.06M	★★★★★★
Stelrad Group (LSE:SRAD)	£1.42	£180.84M	★★★★★☆
Secure Trust Bank (LSE:STB)	£3.55	£67.7M	★★★★☆☆

Click here to see the full list of 5,819 stocks from our Penny Stocks screener.

Let's uncover some gems from our specialized screener.

NagaCorp (SEHK:3918)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: NagaCorp Ltd. is an investment holding company that manages and operates a hotel and casino complex in the Kingdom of Cambodia, with a market cap of HK$12.92 billion.

Operations: The company generates revenue primarily from casino operations, which account for $545.61 million, and hotel and entertainment operations, contributing $23.22 million.

Market Cap: HK$12.92B

NagaCorp Ltd. has faced challenges with declining earnings, showing a 36.2% annual decrease over the past five years and negative growth of 31.8% last year, highlighting volatility in its financial performance. Despite stable weekly volatility and satisfactory debt coverage by cash flow (60.2%), the company struggles with short-term liabilities exceeding assets by $82.8M and reduced profit margins from 30% to 17.7%. Recent board changes include Ms. Monica Lam's resignation as Company Secretary to become a non-executive Director, succeeded by Ms. Sophie Lam, emphasizing continuity in governance expertise amidst operational challenges.

• Navigate through the intricacies of NagaCorp with our comprehensive balance sheet health report here.
• Assess NagaCorp's future earnings estimates with our detailed growth reports.

Wolong Resources Group (SHSE:600173)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Wolong Resources Group Co., Ltd. is involved in the development and sale of real estate properties in China, with a market cap of CN¥2.61 billion.

Operations: The company has not reported any revenue segments.

Market Cap: CN¥2.61B

Wolong Resources Group Co., Ltd. has experienced a challenging financial period, with earnings declining by 81.6% over the past year and profit margins dropping from 3.4% to 1.2%. Despite these setbacks, the company maintains stable weekly volatility and its debt is well covered by operating cash flow (53.1%). Short-term assets of CN¥4.5 billion exceed both short-term liabilities of CN¥2.1 billion and long-term liabilities of CN¥129.7 million, indicating strong liquidity positions despite profitability issues impacted by a large one-off loss of CN¥143.3 million in recent financial results up to September 2024.

• Get an in-depth perspective on Wolong Resources Group's performance by reading our balance sheet health report here.
• Explore historical data to track Wolong Resources Group's performance over time in our past results report.

Zhejiang Yatai Pharmaceutical (SZSE:002370)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Zhejiang Yatai Pharmaceutical Co., Ltd. is engaged in the research, production, sale, and export of pharmaceutical products both in China and internationally, with a market cap of CN¥1.79 billion.

Operations: The company's revenue is derived entirely from the Chinese market, amounting to CN¥425.62 million.

Market Cap: CN¥1.79B

Zhejiang Yatai Pharmaceutical faces financial challenges, reporting a net loss of CN¥3.46 million for the nine months ending September 2024, despite slight revenue growth to CN¥306.84 million from the previous year. The company remains unprofitable but has reduced losses significantly over five years and maintains a strong liquidity position with short-term assets of CN¥904.6 million exceeding liabilities. Shareholder dilution occurred recently, yet the firm holds more cash than debt and boasts an adequate cash runway exceeding three years due to positive free cash flow growth. An upcoming shareholder meeting will address project terminations funded by convertible bonds.

• Unlock comprehensive insights into our analysis of Zhejiang Yatai Pharmaceutical stock in this financial health report.
• Examine Zhejiang Yatai Pharmaceutical's past performance report to understand how it has performed in prior years.

Turning Ideas Into Actions

• Click through to start exploring the rest of the 5,816 Penny Stocks now.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com